Neurocrine Biosciences Inc
$ 130.81
3.55%
14 Apr - close price
- Market Cap 12,677,913,000 USD
- Current Price $ 130.81
- High / Low $ 130.84 / 126.32
- Stock P/E 27.05
- Book Value 32.50
- EPS 4.67
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.16 %
- 52 Week High 160.18
- 52 Week Low 97.30
About
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$184.73
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-10-30 | 2025-07-30 | 2025-05-05 | 2025-02-06 | 2024-10-30 | 2024-08-01 | 2024-05-01 | 2024-02-07 | 2023-10-31 | 2023-08-01 | 2023-05-03 |
| Reported EPS | 1.88 | 2.17 | 1.65 | 0.7 | 1.69 | 1.81 | 0.63 | 0.42 | 1.44 | 0.82 | 0.95 | -0.79 |
| Estimated EPS | 1.86 | 2.09 | 1.5 | 1.09 | 1.93 | 1.82 | 1.05 | 1.01 | 1.15 | 0.97 | 0.78 | 0.13 |
| Surprise | 0.02 | 0.08 | 0.15 | -0.39 | -0.24 | -0.01 | -0.42 | -0.59 | 0.29 | -0.15 | 0.17 | -0.92 |
| Surprise Percentage | 1.0753% | 3.8278% | 10% | -35.7798% | -12.4352% | -0.5495% | -40% | -58.4158% | 25.2174% | -15.4639% | 21.7949% | -707.6923% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NBIX
2026-04-14 20:09:02
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that it will host a conference call and webcast to discuss its first quarter 2026 financial results. The event is scheduled for May 5, 2026, at 1:30 p.m. Pacific Time. The announcement provides details for investors and interested parties to access company updates.
2026-04-14 20:09:02
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has scheduled its first quarter 2026 financial results conference call and webcast for May 5, 2026, at 1:30 p.m. Pacific Time. The press release will be issued earlier on the same day. Details for accessing the call and webcast replay are provided for investors.
2026-04-14 20:09:02
Neurocrine Biosciences (Nasdaq: NBIX) will release its Q1 2026 financial results and host a conference call and webcast on May 5, 2026. The press release is scheduled for 1:00 p.m. PT / 4:00 p.m. ET, with the live conference call and webcast beginning at 1:30 p.m. PT / 4:30 p.m. ET. A replay of the webcast will be available for approximately one month on the company's investors website.
2026-04-14 12:39:54
Neurocrine Biosciences announced new real-world evidence showing that adult patients with tardive dyskinesia treated with INGREZZA (valbenazine) capsules demonstrated higher treatment persistence compared to those on AUSTEDO XR (deutetrabenazine). These findings are being presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting. This analysis highlights INGREZZA's potentially better long-term patient adherence in real-world clinical settings.
2026-04-13 12:09:45
Neurocrine Biosciences is set to acquire Soleno Therapeutics for $2.9 billion, expanding its rare disease drug portfolio. The acquisition includes Vykat XR, an FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, which is expected to bolster Neurocrine's already strong sales from Ingrezza and Crenessity. This move aims to leverage Neurocrine's commercial capabilities to broaden the reach of Vykat XR to more patients.
2026-04-13 07:09:02
Nxera Pharma's partner Neurocrine Biosciences has dosed the first patient in a Phase 2 clinical study for NBI-1117570, an investigational oral drug for adults with schizophrenia. This milestone triggers a US$22.5 million payment to Nxera Pharma, which will be recognized as revenue in Q1 FY2026. NBI-1117570 is a dual muscarinic M1/M4 selective receptor agonist developed using Nxera's NxWave™ platform, and the study aims to evaluate its efficacy, safety, and tolerability in approximately 120 patients.
